HER2 Positive Breast Cancer By Manish Singhal
Session 3 : HER2 Positive Breast Cancer
Chairpersons :
D C Doval, CJ Tamane
Speaker :
Manish Singhal
Final analysis of WSG-ADAPT HER2+/H2+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab + endocrine therapy in HER2-positive hormone receptor-positive early breast cancer
Author: Harbeck N
Conference: SABCS
Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2 positive hormone-receptor positive early breast cancer: WSGADAPTHER2/ HR phase II trial
Author: Harbeck 2
Conference: ASCO
Phase III, randomized study of trastuzumab emtasine (T Dm 1),Pertuzumab (P) vs trastuzumab taxane (HT) for first line treatmentOf HER2 positive MBC: primary results from MARIANNE study
Author: P A Ellis
Conference: ASCO